List of Letairis drug patents

Letairis is owned by Gilead.

Letairis contains Ambrisentan.

Letairis has a total of 3 drug patents out of which 0 drug patents have expired.

Letairis was authorised for market use on 15 June, 2007.

Letairis is available in tablet;oral dosage forms.

Letairis can be used as for the treatment of pulmonary hypertension (pah) in combination with tadalafil, for the treatment of pulmonary arterial hypertension (pah) in combination with tadalafil, wherein the weight ratio of ambrisentan to tadalafil is about 1:2 to about 1:3.

The generics of Letairis are possible to be released after 14 October, 2031.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9474752 GILEAD Method for treating a pulmonary hypertension condition
Dec, 2027

(4 years from now)

US8377933 GILEAD Method for treating a pulmonary hypertension condition
Dec, 2027

(4 years from now)

US9549926 GILEAD Compositions and methods of treating pulmonary hypertension
Oct, 2031

(8 years from now)

Drugs and Companies using AMBRISENTAN ingredient

Market Authorisation Date: 15 June, 2007

Treatment: For the treatment of pulmonary hypertension (pah) in combination with tadalafil; For the treatment of pulmonary arterial hypertension (pah) in combination with tadalafil, wherein the weight ratio of ambrisentan to tadalafil is about 1:2 to about 1:3

Dosage: TABLET;ORAL

How can I launch a generic of LETAIRIS before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in